JP2023515466A5 - - Google Patents
Info
- Publication number
- JP2023515466A5 JP2023515466A5 JP2022549789A JP2022549789A JP2023515466A5 JP 2023515466 A5 JP2023515466 A5 JP 2023515466A5 JP 2022549789 A JP2022549789 A JP 2022549789A JP 2022549789 A JP2022549789 A JP 2022549789A JP 2023515466 A5 JP2023515466 A5 JP 2023515466A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- eeg
- administration
- decreased
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025281702A JP2026075094A (ja) | 2020-02-21 | 2025-12-25 | Ｈｔｔの発現を低下させる方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980010P | 2020-02-21 | 2020-02-21 | |
| US62/980,010 | 2020-02-21 | ||
| PCT/US2021/018681 WO2021168183A1 (en) | 2020-02-21 | 2021-02-19 | Methods for reducing htt expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025281702A Division JP2026075094A (ja) | 2020-02-21 | 2025-12-25 | Ｈｔｔの発現を低下させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515466A JP2023515466A (ja) | 2023-04-13 |
| JP2023515466A5 true JP2023515466A5 (enExample) | 2024-02-28 |
Family
ID=77391689
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549789A Pending JP2023515466A (ja) | 2020-02-21 | 2021-02-19 | Ｈｔｔの発現を低下させる方法 |
| JP2025281702A Pending JP2026075094A (ja) | 2020-02-21 | 2025-12-25 | Ｈｔｔの発現を低下させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025281702A Pending JP2026075094A (ja) | 2020-02-21 | 2025-12-25 | Ｈｔｔの発現を低下させる方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230108340A1 (enExample) |
| EP (1) | EP4107269A4 (enExample) |
| JP (2) | JP2023515466A (enExample) |
| KR (1) | KR20220144837A (enExample) |
| CN (1) | CN115279903A (enExample) |
| AU (1) | AU2021224729A1 (enExample) |
| BR (1) | BR112022016370A2 (enExample) |
| CA (1) | CA3172336A1 (enExample) |
| IL (1) | IL295625A (enExample) |
| MX (1) | MX2022010204A (enExample) |
| WO (1) | WO2021168183A1 (enExample) |
| ZA (1) | ZA202209112B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025265013A2 (en) | 2024-06-20 | 2025-12-26 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2422819B1 (en) * | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
| EP3626823A1 (en) * | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| WO2015051318A1 (en) * | 2013-10-04 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
| US20170044538A1 (en) * | 2014-04-17 | 2017-02-16 | Biogen Ma Inc. | Compositions and Methods for Modulation of SMN2 Splicing in a Subject |
| CN117965536A (zh) * | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| US11268093B2 (en) * | 2017-01-03 | 2022-03-08 | Rula Zain-Luqman | Therapeutic method for huntington's disease |
| KR20220030271A (ko) * | 2019-06-28 | 2022-03-10 | 더 펜 스테이트 리서어치 파운데이션 | 헌팅턴병을 치료하기 위한 방법 및 재료 |
-
2021
- 2021-02-19 US US17/800,785 patent/US20230108340A1/en not_active Abandoned
- 2021-02-19 AU AU2021224729A patent/AU2021224729A1/en active Pending
- 2021-02-19 EP EP21757534.9A patent/EP4107269A4/en not_active Withdrawn
- 2021-02-19 BR BR112022016370A patent/BR112022016370A2/pt not_active Application Discontinuation
- 2021-02-19 KR KR1020227032214A patent/KR20220144837A/ko active Pending
- 2021-02-19 CA CA3172336A patent/CA3172336A1/en active Pending
- 2021-02-19 IL IL295625A patent/IL295625A/en unknown
- 2021-02-19 WO PCT/US2021/018681 patent/WO2021168183A1/en not_active Ceased
- 2021-02-19 CN CN202180016151.4A patent/CN115279903A/zh active Pending
- 2021-02-19 MX MX2022010204A patent/MX2022010204A/es unknown
- 2021-02-19 JP JP2022549789A patent/JP2023515466A/ja active Pending
-
2022
- 2022-08-15 ZA ZA2022/09112A patent/ZA202209112B/en unknown
-
2025
- 2025-12-25 JP JP2025281702A patent/JP2026075094A/ja active Pending
-
2026
- 2026-04-27 US US19/659,031 patent/US20260234628A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525030A5 (enExample) | ||
| DE69620906T2 (de) | Antisense-oligonukleotidmodulation der raf-genexpression | |
| JP6902869B2 (ja) | アタキシン２の発現を調節するための組成物 | |
| US12104155B2 (en) | UNC13A antisense oligonucleotides | |
| Raffler et al. | L-selectin in inflammation, infection and immunity | |
| KR20200079304A (ko) | Snca 발현을 감소시키기 위한 화합물 및 방법 | |
| RU2020127049A (ru) | Модуляторы экспрессии dnm2 | |
| JP2021511072A5 (enExample) | ||
| CN119790152A (zh) | 使用unc13a基因转录本的调节剂治疗神经系统疾病 | |
| EP4093409A1 (en) | Antagonism as a therapy for tdp-43 proteinopathies | |
| TW202140787A (zh) | 用於調節ｓｍｎ２之化合物及方法 | |
| US20190112608A1 (en) | Methods of using smad7 antisense oligonucleotides | |
| EP4652276A2 (en) | Unc13a antisense oligonucleotides | |
| CN115518161B (zh) | Zip1作为癫痫治疗靶标的应用 | |
| WO2025101991A1 (en) | Methods for modulating ube3a-ats | |
| US20200009181A1 (en) | Novel Approach for Treating Cancer | |
| JPH05501199A (ja) | 全身性免疫機能不全に関連する神経―知覚疾患の診断及び治療 | |
| US20230108340A1 (en) | Methods for reducing htt expression | |
| CN117357550A (zh) | miR-22及其和DNA四面体的复合物在制备治疗抑郁症的药物中的用途 | |
| CN106999607A (zh) | 非编码rna malat‑1是调控学习和记忆的靶标 | |
| US20210139906A1 (en) | Compounds and methods for reducing spdef expression | |
| WO2013051435A1 (ja) | 治療剤、遺伝子治療剤及び好酸球の浸潤抑制方法 | |
| Caires et al. | Influence of genetic regulatory effects modified by environmental immune activation on periapical disease | |
| JP2025500438A5 (enExample) | ||
| JP7267922B2 (ja) | 新規製剤 |